CBD Oil Shortage for French Medical Experimentation

The fears of the patients turned out to be real. Last week, reports emerged of a possible shortage of CBD oil and medical cannabis products in France. Now, communications with the experiment’s stakeholders have confirmed the situation, with the French medical study losing supply of CBD oil from Little Green Pharma, which represented about 60% of the products prescribed and without existing stock.

The fears of the patients turned out to be real. Last week, reports emerged of a possible shortage of CBD oil and medical cannabis products in France. Now, communications with the experiment’s stakeholders have confirmed the situation.

To follow the latest updates on this CBD oil story, along with the latest research and legalization from around the world, download our free cannabis news app.

French Experiment to Lose Access to CBD Oil

The French medical experimentation will thus lose its supply of pharmaceutical CBD oil without THC – CBD oil from Little Green Pharma – which represented about 60% of the products prescribed and without existing stock.

According to our information, the laboratory in charge of supplying CBD oil does not wish to continue to offer its product either for free or at 14€ per bottle, a price well below its manufacturing, transport, and customs costs, as proposed in the call for tenders of the Ministry of Health for the extension of the experiment.

Proposal to Replace CBD Oil with Alternatives

The proposals made for patients who are treated with this CBD oil are to replace it :

• for stabilized epileptic children with Epidyolex
• for stabilized adults suffering from spasticity and/or multiple sclerosis by a CBD:THC 20:1 oil

Adult patients who have found satisfaction in a pure CBD (without THC) should therefore change treatment and experiment with a new CBD oil with THC, which some know they cannot tolerate.

Is the Directorate General of Health to Blame?

Once again, the role of the Directorate General of Health (DGS) is widely pointed out, by many sources that we contacted, for its lack of anticipation and its lack of interest around this experimentation to the detriment of sick people.

Some, such as Yann Bisiou, a specialist in drug law, express it in a confrontational way:

“We find CBD oil in stores on every corner, and the DGS is not able to find pharmaceutical CBD oil. The legal fragility of the device chosen by the DGS was clearly constituted and a source of litigation. Either they are incompetent, or they want to sink the experimentation,” he confided.

Looking at the call for CBD oil tenders, which was available online, we can see that the financing for the extension of the experiment was taken from the budget of the associations of patient victims of therapeutic accidents. A sign, if it were necessary, that the DGS takes the experimentation of therapeutic cannabis and CBD oil in France very lightly. A “scandalous and shameful” situation for Yann Bisiou.

Seeking Solutions to CBD Oil Shortage

From our understanding, the DGS has also realized late that a product had not found a buyer in the context of the call for tenders that concerned the extension of the experimentation, despite the numerous alerts of manufacturers. Since then, it has been trying to find solutions to avoid a CBD oil shortage.

It would also be in this context that it has hastily bypassed the ANSM, normally competent on the subject, the CBD-based drugs from the list of narcotics to place them on the list of poisonous substances, as announced by Nicolas Authier last week. This change in classification would be aimed at reducing the costs of importing CBD oil. The legal trade of “narcotics” is extremely controlled and expensive and thus facilitates the supply of experimentation.

A change that could have been made before the shortage, and which could lead to a return of the missing oil for patients? And how soon?

We are now waiting to see how the DGS acts in response to the CBD oil shortage.

—

(Featured image by Tara Winstead via Pexels)

DISCLAIMER: This article was written by a third-party contributor and does not reflect the opinion of Hemp.im, its management, staff, or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the company may believe that its expectations are based on reasonable assumptions, the actual results that the company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in Newsweed, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.